Ask about this productRelated genes to: WARS antibody
- Gene:
- WARS NIH gene
- Name:
- tryptophanyl-tRNA synthetase
- Previous symbol:
- IFI53
- Synonyms:
- IFP53
- Chromosome:
- 14q32.2
- Locus Type:
- gene with protein product
- Date approved:
- 2001-06-22
- Date modifiied:
- 2014-11-19
Related products to: WARS antibody
Related articles to: WARS antibody
- Military nursing operates at the intersection of healthcare and defense, requiring nurses to balance professional ethics with military discipline, operational readiness, and organizational hierarchy. - Source: PubMed
Publication date: 2026/08/15
Prosen MirkoKvržić Zlatko - Alopecia areata (AA), an autoimmune disease, causes hair loss on the scalp, face, and body, with a prevalence of approximately 2% in the Middle East. AA is associated with significant impacts to patient quality of life (QoL). This study described dermatologist perceptions and experiences treating AA in the Kingdom of Saudi Arabia (KSA) while new treatments were introduced, and examined patient disease burden and unmet treatment need. - Source: PubMed
Publication date: 2026/08/14
Al Ajlan Mohammed Abdulaziz FAlenzi Khalidah AAl-Haddab Mohammed AAlHarbi IbtisamAlturaiki AbdulrahmanArsalan Mohammad SaeedBehiry AymanKurosky Samantha KEncinas Gerardo AAnderson PeterCha-Silva Ashley SVaghela ShailjaCanosa Juliana Machado - Armed conflicts impose a substantial burden of traumatic injuries, particularly in low-resource settings where health systems are already strained. Abdominal trauma is among the most common and life-threatening injuries in modern warfare, often requiring urgent surgical intervention. Despite the scale of the ongoing conflict in Sudan, there is a lack of empirical data describing the patterns, management, and outcomes of abdominal trauma in this setting. - Source: PubMed
Publication date: 2026/08/13
Khair Mugahid MElsharif Swsan A MMohamed Abdarheem Mohamed IbrahimHamza Abdullahi Aamir AAbass Alameen O ADowa Alyaqeen EissaAlhaj Aziza Emadaldeen FakhreyDowa Bara'a EissaAli EsraTaha Mariam Abdelgadir HagoMohamed Suliman EshagAbdallah Weaam - Haematopoietic stem cell transplantation (HSCT) from an HLA-identical sibling is the primary curative therapy for acquired aplastic anaemia (AA). Outcomes from large cohorts in low- and middle-income countries are scarce. - Source: PubMed
Publication date: 2026/08/14
Khan MaryamSamad Shafaq AbdulAltaf SadafGhani DanyalSarwar ShahzadChaudhry Qamar Un NisaMehmood Syed KamranFarzana TasneemZaidi UzmaAli NatashaShahbaz NighatKhan Mehreen AliAwais Kashaf Ad DujaAdil SalmanMir Muhammad AyazGhafoor TariqKhattak Tariq AzamBatool AliyaBukhari Syed Nasir AbbasKhurram SanaSatti Tariq MahmoodTariq HiraAhmed ParvezIftikhar Raheel - The rapid global emergence of multidrug-resistant (MDR) bacterial pathogens has significantly reduced the effectiveness of conventional antibiotics, creating an urgent need for alternative antimicrobial strategies. Among emerging precision therapeutics bacteriophage therapy and Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)-Cas systems have shown to have strong potential through highly specific bacterial targeting mechanisms. Bacteriophages have the ability to replicate themselves and penetrate biofilms, and the ability of CRISPR-Cas systems to edit the genes responsible for antimicrobial resistance, virulence factors, and the mobile genetic elements that underlie bacterial resistance. The recent advancement enabled the integration of these technologies through CRISPR-armed bacteriophages, which utilize bacteriophages as delivery mechanisms for CRISPR and address the large populations of MDR bacteria. Compared to administering CRISPR and bacteriophage independently, the current data suggest that the use of these two methods synergistically will lead to greater efficacy of delivery, specific targeting of resistance determinants, decreased risk of resistance development, and minimal impact on the body's beneficial microorganisms. While the potential combination of these approaches holds great promise to help combat the issue of MDR bacteria, there are still numerous barriers to overcome in order to implement these methods which include narrow phage host range, bacterial escape mechanisms, off-target CRISPR activity, anti-CRISPR proteins, host immune responses, and unresolved manufacturing and regulatory limitations. This review critically examines bacteriophage-based antimicrobials, CRISPR-Cas therapeutic systems, and their emerging integration as CRISPR-armed phages, highlighting their comparative advantages, current limitations, and future potential as promising targeted antimicrobial approach platforms requiring further clinical validation. - Source: PubMed
Publication date: 2026/08/14
Musini AnjaneyuluYata Vinod KumarBukke Sarad Pawar NaikAkhila KalalShivani TeetlaNarapureddy Bayapa ReddyThalluri ChandrashekarMohamed Awad Osman AbdallaAdam Mohammed Dhawelbate Mohammed